{
    "id": "4e63b36e-3d75-b3b0-42b6-f2f3c1ddf4d0",
    "indications": "Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )",
    "contraindications": "Do not combine everolimus tablets and AFINITOR DISPERZ to achieve the total daily dose. ( 2.1 ) Modify the dose for patients with hepatic impairment or for patients taking drugs that inhibit or induce P-glycoprotein (P-gp) and CYP3A4. ( 2.1 ) Breast Cancer: 10 mg orally once daily. ( 2.2 ) TSC-Associated Renal Angiomyolipoma: 10 mg orally once daily. ( 2.5 ) TSC-Associated SEGA: 4.5 mg/m 2 orally once daily; adjust dose to attain trough concentrations of 5-15 ng/mL. ( 2.6 , 2.8 )",
    "warningsAndPrecautions": "Everolimus tablets\n                  2.5 mg tablets: White to off white, capsule shaped, flat faced bevelled edge tablet debossed with B 2.5 on one side and plain on other side; available in:\n                  \n                  Bottle of 30 tablets with child resistant closure ------------------------ NDC 70377-010-11\n                  Blisters of 28 tablets ------------------------------------------------------- NDC 70377-010-22\n                  Blisters of 28 tablets (Desiccant Embedded Alu-Alu Blister pack) --NDC 70377-010-23\n                  Each carton contains 4 blister cards of 7 tablets each\n                  \n                  5 mg tablets: White to off white, capsule shaped, flat faced bevelled edge tablet debossed with B 5 on one side and plain on other side; available in:\n                  \n                  Bottle of 30 tablets with child resistant closure ------------------------ NDC 70377-011-11\n                  Blisters of 28 tablets ------------------------------------------------------- NDC 70377-011-22\n                  Blisters of 28 tablets (Desiccant Embedded Alu-Alu Blister pack)-- NDC 70377-011-23\n                  Each carton contains 4 blister cards of 7 tablets each\n                  \n                  7.5 mg tablets: White to off white, capsule shaped, flat faced bevelled edge tablet debossed with B 7.5 on one side and plain on other side; available in:\n                  \n                  Bottle of 30 tablets with child resistant closure ------------------------ NDC 70377-012-11\n                  Blisters of 28 tablets ------------------------------------------------------- NDC 70377-012-22\n                  Blisters of 28 tablets (Desiccant Embedded Alu-Alu Blister pack)-- NDC 70377-012-23\n                  Each carton contains 4 blister cards of 7 tablets each\n                  \n                  10 mg tablets: White to off white, capsule shaped, flat faced bevelled edge tablet debossed with B 10 on one side and plain on other side; available in:\n                  \n                  Bottle of 30 tablets with child resistant closure ------------------------ NDC 70377-013-11\n                  Blisters of 28 tablets ------------------------------------------------------- NDC 70377-013-22\n                  Blisters of 28 tablets (Desiccant Embedded Alu-Alu Blister pack)-- NDC 70377-013-23\n                  Each carton contains 4 blister cards of 7 tablets each\n                  \n                  Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature.\n                  \n                  Store in the original container, protect from light and moisture.\n                  Follow special handling and disposal procedures for anticancer pharmaceuticals.1",
    "adverseReactions": "Everolimus tablets are contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives [see Warnings and Precautions (5.3)].",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYPROMELLOSE 2208 (3 MPA.S)",
            "code": "9H4L916OBU"
        },
        {
            "name": "Everolimus",
            "code": "9HW64Q8G6G"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "organization": "Biocon Pharma Inc.",
    "name": "EVEROLIMUS",
    "effectiveTime": "20250321"
}